Though the limited available studies do not clearly establish a link between OPG serum levels and the risk of breast cancer in BRCA mutation carriers, these findings suggest a potential mechanism that warrants further investigation, particularly given the elevated breast cancer risk in the BRCA carrier patient population. The gene discussed is TNFRSF11B; the disease is breast cancer.